All Photos(1)
3-(1,1-Dimethylethyl)-6-[4-(2,4,5-trifluorophenyl)-5-oxazolyl]-1,2,4-triazolo[4,3-a]pyridine, 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)-1,3-oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine, 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine, 5-(3-tert-Butyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-4-(2,4,5-trifluorophenyl)oxazole, CP944629
C19H15F3N4O
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
room temp
SMILES string
CC(C)(C)C1=NN=C2C=CC(C3=C(C4=C(F)C=C(F)C(F)=C4)N=CO3)=CN21
InChI
1S/C19H15F3N4O/c1-19(2,3)18-25-24-15-5-4-10(8-26(15)18)17-16(23-9-27-17)11-6-13(21)14(22)7-12(11)20/h4-9H,1-3H3
InChI key
VNZJNPIWZYMGAO-UHFFFAOYSA-N
Biochem/physiol Actions
CP-9446219 is a potent p38alpha (p38α) inhibitor (IC50 = 1.8 nM) with no inhibitory potency against a panel of 26 other knases (IC50 >10 μM), including p38gamma (p38γ) and p38delta (p38δ), MKK1, MAPK2/ERK2, JNK, MAPKAP-K1a, and MAPKAP-K2. CP-944629 effectively inhibits LPS-stimulated cellular TNF-α production in vitro (IC50 = 63 and 8.3 nM, using human whole blood and isolated mononuclear cells, respectively) and in rats in vivo (ED50 = 0.1 mg/kg p.o.) with good pharmacokinetic profile and oral availability (F = 66%/monkey, 54%/rat).
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service